Azenta has named Trey Martin president of its multiomics business, effective April 6, 2026, replacing Ginger Zhou, who will stay on in an advisory role through November 2026.
The move is aimed at speeding execution of Azenta’s multiomics long-range plan, with a focus on scaling global synthesis capabilities, improving operational performance, tightening commercial discipline and pushing profitable growth across the platform.
Martin arrives from Maravai Life Sciences, where he was chief executive officer and a board member. Before that, he held senior roles at Danaher, including senior vice president of genomic medicines and president of Integrated DNA Technologies. At IDT, he spent more than two decades and helped drive global expansion through organic and inorganic investments, with double-digit growth over the period.
Azenta CEO John Marotta said Martin has more than 30 years of leadership experience across life sciences operations and is positioned to lead the next phase of the company’s multiomics strategy.
Zhou’s exit marks a leadership change as Azenta advances the plan it outlined at its December 2025 investor day. Martin said he sees opportunities to further differentiate and scale Azenta’s genomics services and synthesis capabilities and to deliver sustainable, profitable growth. Following these announcements, the company's shares moved -2.52%, and are now trading at a price of $21.31. If you want to know more, read the company's complete 8-K report here.
